A PHASE 1/2, MULTICENTER, OPEN-LABEL, STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN, AND EVALUATE THE SAFETY AND<br />PRELIMINARY EFFICACY OF CC-92480 IN COMBINATION WITH STANDARD TREATMENTS IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) AND NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

CC-92480-MM-002

Comprehensive Cancer Center Mainfranken

Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)

Plasmozytom (Multiples Myelom)

Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)

Phase I/II

Herr Dr. Leo Rasche

Herr Prof. Dr. Martin Kortüm

Frau Dr Katharina Herzog

Medizinische Klinik II, Schwerpunkt Hämatologie/Onkologie

Universitätsklinikum Würzburg

> Drittlinie

Therapeutisch